Pathways to ensure universal and affordable access to hepatitis C treatment

Autor: Caitlin H. Douglass, Alisa Pedrana, Jeffrey V. Lazarus, Ellen F. M. ‘t Hoen, Radi Hammad, Ricardo Baptista Leite, Andrew Hill, Margaret Hellard

Publikováno v: BMC Medicine, Vol 16, Iss 1, Pp 1-9 (2018)

Abstract Direct-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C treatment and prevention. The World Health Organization has called for the elimination of hepatitis C as a public health threat by 2030. However, the disc

Externí odkaz: https://doaj.org/article/0178f62a870e4b308028bfd30d00d42f

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Autor: Benedetta Massetto, Imam Waked, Mohamed Elbasiony, Sophia Lu, Mohamed Hassany, Kathryn Kersey, Radi Hammad, Diana M. Brainard, Aisha Elsharkawy, John G. McHutchison, Wahid Doss, Gamal Esmat, Gamal Shiha, Anu Osinusi, Talaat Zakareya, Reham Soliman, Wael Abdel-Razek, Rabab Fouad

Publikováno v: Gut

ObjectiveWe evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had fai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec92c79af6899f6840d5b4857a3f3b0e
http://europepmc.org/articles/PMC6580781

Pathways to ensure universal and affordable access to hepatitis C treatment

Autor: Radi Hammad, Andrew Hill, Ricardo Baptista Leite, Jeffrey V. Lazarus, Margaret Hellard, Caitlin H. Douglass, Ellen 't Hoen, Alisa Pedrana

Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
BMC Medicine
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Dipòsit Digital de la UB
Universidad de Barcelona
Web of Science
BMC Medicine, 16:175. BMC

Direct-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C treatment and prevention. The World Health Organization has called for the elimination of hepatitis C as a public health threat by 2030. However, the discrepancy i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e556257239d8deeb80b9a7e064988e5

Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis

Autor: Radi Hammad, G. Van Dooren, I. Lonjon-Domanec, M. Gamil, Mohamed Hassany, E. A. Sameea, M. K. Ashour, Ralph DeMasi, M. El Raziky, M. S. Hashim, Wahid Doss, Imam Waked, Y. Hamada, Sofia Keim

Publikováno v: Journal of viral hepatitis. 24(2)

The OSIRIS study investigated efficacy and safety of simeprevir plus sofosbuvir for eight or 12 weeks in hepatitis C virus (HCV) genotype 4-infected patients with METAVIR F0-F4 fibrosis. Sixty-three patients (33 treatment-naive and 30 peg-interferon/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4486280827d84b98ddf31c3c3a977b
https://pubmed.ncbi.nlm.nih.gov/27790789

P1346 : Study protocol for a partly randomised, open-label phase IIA trial of once-daily simeprevir combined with sofosbuvir for the treatment of HCV genotype 4 infected patients with or without cirrhosis (OSIRIS)

Autor: Imam Waked, G. Van Dooren, I. Lonjon-Domanec, Asmaa Gomaa, M. Gamil, Sofia Keim, M.S. Hashem, M. El Raziky, Ralph DeMasi, Marwa Khairy, Wahid Doss, Radi Hammad, A. El Sharkawy, Mohamed Hassany

Publikováno v: Journal of Hepatology. 62:S861-S862

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d75034c1a65727449a30ac247e604d28
https://doi.org/10.1016/s0168-8278(15)31525-7